|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
45,766,000 |
Market
Cap: |
1.02(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.29 - $33.79 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 8 |
Insider 6 Months : 8 |
Insider 3/6 Months : 16.5 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. Co.'s product portfolio are: ENROUTE Transcarotid Neuroprotection System, which is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, which is a self-expanding, self-tapering stent that conforms to patient; ENHANCE Transcarotid Peripheral Access Kit, which is used in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire, which is used for navigating and crossing the target lesion for delivery of interventional devices.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
11,700 |
11,700 |
11,700 |
11,700 |
Total Buy Value |
$198,783 |
$198,783 |
$198,783 |
$198,783 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
1 |
1 |
1 |
1 |
Total Shares Sold |
27,257 |
27,257 |
40,770 |
602,067 |
Total Sell Value |
$483,218 |
$483,218 |
$770,629 |
$28,445,866 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
6 |
6 |
13 |
58 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,675 |
94,085 |
|
- |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-03-16 |
4 |
AS |
$30.25 |
$3,025 |
D/D |
(100) |
89,410 |
|
74% |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-03-16 |
4 |
OE |
$1.60 |
$160 |
D/D |
100 |
89,510 |
|
- |
|
Rogers Erica J. |
President and CEO |
|
2020-03-11 |
4 |
AS |
$37.36 |
$748,942 |
D/D |
(20,044) |
97,546 |
|
26% |
|
Rogers Erica J. |
President and CEO |
|
2020-03-11 |
4 |
OE |
$1.38 |
$27,661 |
D/D |
20,044 |
117,590 |
|
- |
|
Ruedy Richard |
EVPClin&Reg.Affairs&QA |
|
2020-03-04 |
4 |
OE |
$1.38 |
$11,040 |
D/D |
8,000 |
15,794 |
|
- |
|
Davis Andrew S. |
EVPGlobal Sales& Marketing |
|
2020-03-02 |
4 |
AS |
$40.33 |
$267,590 |
D/D |
(6,635) |
13,540 |
|
8% |
|
Davis Andrew S. |
EVPGlobal Sales& Marketing |
|
2020-03-02 |
4 |
OE |
$1.46 |
$9,687 |
D/D |
6,635 |
20,175 |
|
- |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-02-18 |
4 |
AS |
$46.79 |
$449,212 |
D/D |
(9,600) |
89,410 |
|
-18% |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-02-18 |
4 |
OE |
$1.60 |
$15,360 |
D/D |
9,600 |
93,031 |
|
- |
|
Rogers Erica J. |
President and CEO |
|
2020-02-11 |
4 |
AS |
$47.43 |
$950,647 |
D/D |
(20,044) |
97,546 |
|
-13% |
|
Rogers Erica J. |
President and CEO |
|
2020-02-11 |
4 |
OE |
$1.38 |
$27,661 |
D/D |
20,044 |
117,590 |
|
- |
|
Davis Andrew S. |
EVPGlobal Sales& Marketing |
|
2020-02-03 |
4 |
AS |
$46.70 |
$309,880 |
D/D |
(6,635) |
13,540 |
|
-20% |
|
Davis Andrew S. |
EVPGlobal Sales& Marketing |
|
2020-02-03 |
4 |
OE |
$1.46 |
$9,687 |
D/D |
6,635 |
20,175 |
|
- |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-01-15 |
4 |
AS |
$41.78 |
$401,066 |
D/D |
(9,600) |
89,410 |
|
-7% |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2020-01-15 |
4 |
OE |
$1.60 |
$15,360 |
D/D |
9,600 |
99,010 |
|
- |
|
Rogers Erica J. |
President and CEO |
|
2020-01-13 |
4 |
AS |
$40.53 |
$812,341 |
D/D |
(20,044) |
97,546 |
|
-6% |
|
Rogers Erica J. |
President and CEO |
|
2020-01-13 |
4 |
OE |
$1.38 |
$27,661 |
D/D |
20,044 |
117,590 |
|
- |
|
Davis Andrew S. |
EVPGlobal Sales& Marketing |
|
2020-01-02 |
4 |
AS |
$39.94 |
$264,980 |
D/D |
(6,635) |
13,540 |
|
-5% |
|
Davis Andrew S. |
EVPGlobal Sales& Marketing |
|
2020-01-02 |
4 |
OE |
$1.46 |
$9,687 |
D/D |
6,635 |
20,175 |
|
- |
|
Ruedy Richard |
EVPClin&Reg.Affairs&QA |
|
2019-12-23 |
4 |
OE |
$1.35 |
$9,999 |
D/D |
7,407 |
7,794 |
|
- |
|
Buchanan Lucas W. |
Chief Financial Officer |
|
2019-12-18 |
4 |
OE |
$4.73 |
$36,080 |
D/D |
7,628 |
89,410 |
|
- |
|
Ruedy Richard |
EVPClin&Reg.Affairs&QA |
|
2019-12-18 |
4 |
AS |
$35.55 |
$355,500 |
I/I |
(10,000) |
70 |
|
- |
|
Ruedy Richard |
EVPClin&Reg.Affairs&QA |
|
2019-12-18 |
4 |
AS |
$38.00 |
$1,224,436 |
D/D |
(32,222) |
387 |
|
- |
|
Ruedy Richard |
EVPClin&Reg.Affairs&QA |
|
2019-12-18 |
4 |
OE |
$0.68 |
$21,911 |
D/D |
32,222 |
32,609 |
|
- |
|
410 Records found
|
|
Page 14 of 17 |
|
|